These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 14639106)

  • 1. HER-2/neu protein expression and gene alteration in stage I-IIIA non-small-cell lung cancer: a study of 140 cases using a combination of high throughput tissue microarray, immunohistochemistry, and fluorescent in situ hybridization.
    Tan D; Deeb G; Wang J; Slocum HK; Winston J; Wiseman S; Beck A; Sait S; Anderson T; Nwogu C; Ramnath N; Loewen G
    Diagn Mol Pathol; 2003 Dec; 12(4):201-11. PubMed ID: 14639106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of prognostic implications of HER-2/neu abnormalities in 345 stage I non-small cell carcinomas (NSCLC) and 207 stage I-III neuroendocrine tumours (NET) of the lung.
    Pelosi G; Del Curto B; Dell'Orto P; Pasini F; Veronesi G; Spaggiari L; Maisonneuve P; Iannucci A; Terzi A; Lonardoni A; Viale G
    Int J Cancer; 2005 Jan; 113(1):101-8. PubMed ID: 15386424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents.
    Bunn PA; Helfrich B; Soriano AF; Franklin WA; Varella-Garcia M; Hirsch FR; Baron A; Zeng C; Chan DC
    Clin Cancer Res; 2001 Oct; 7(10):3239-50. PubMed ID: 11595720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between encoded protein overexpression and copy number of the HER2 gene with survival in non-small cell lung cancer.
    Nakamura H; Saji H; Ogata A; Hosaka M; Hagiwara M; Kawasaki N; Kato H
    Int J Cancer; 2003 Jan; 103(1):61-6. PubMed ID: 12455054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas.
    Hirsch FR; Varella-Garcia M; Franklin WA; Veve R; Chen L; Helfrich B; Zeng C; Baron A; Bunn PA
    Br J Cancer; 2002 May; 86(9):1449-56. PubMed ID: 11986780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AQUA and FISH analysis of HER-2/neu expression and amplification in a small cell lung carcinoma tissue microarray.
    Giltnane JM; Murren JR; Rimm DL; King BL
    Histopathology; 2006 Aug; 49(2):161-9. PubMed ID: 16879393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of immunohistochemical expressions of p53, HER-2/neu, and bcl-2 in stage I non-small-cell lung cancer.
    Han H; Landreneau RJ; Santucci TS; Tung MY; Macherey RS; Shackney SE; Sturgis CD; Raab SS; Silverman JF
    Hum Pathol; 2002 Jan; 33(1):105-10. PubMed ID: 11823980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER-2/neu expression in archival non-small cell lung carcinomas using FDA-approved Hercep test.
    Scheurle D; Jahanzeb M; Aronsohn RS; Watzek L; Narayanan R
    Anticancer Res; 2000; 20(3B):2091-6. PubMed ID: 10928158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms.
    Wu Y; Soslow RA; Marshall DS; Leitao M; Chen B
    Gynecol Oncol; 2004 Dec; 95(3):570-5. PubMed ID: 15581965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER-2 status in breast cancer: correlation of gene amplification by FISH with immunohistochemistry expression using advanced cellular imaging system.
    Ciampa A; Xu B; Ayata G; Baiyee D; Wallace J; Wertheimer M; Edmiston K; Khan A
    Appl Immunohistochem Mol Morphol; 2006 Jun; 14(2):132-7. PubMed ID: 16785779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER-2/neu amplification is an independent prognostic factor in gastric cancer.
    Park DI; Yun JW; Park JH; Oh SJ; Kim HJ; Cho YK; Sohn CI; Jeon WK; Kim BI; Yoo CH; Son BH; Cho EY; Chae SW; Kim EJ; Sohn JH; Ryu SH; Sepulveda AR
    Dig Dis Sci; 2006 Aug; 51(8):1371-9. PubMed ID: 16868827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No strong association between HER-2/neu protein overexpression and gene amplification in high-grade invasive urothelial carcinomas.
    Caner V; Turk NS; Duzcan F; Tufan NL; Kelten EC; Zencir S; Dodurga Y; Bagci H; Duzcan SE
    Pathol Oncol Res; 2008 Sep; 14(3):261-6. PubMed ID: 18415713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of gene amplification and protein expression of HER-2/neu in esophageal squamous cell carcinoma using Fluorescence in situ Hybridization (FISH) and immunohistochemistry.
    Sato-Kuwabara Y; Neves JI; Fregnani JH; Sallum RA; Soares FA
    BMC Cancer; 2009 Jan; 9():6. PubMed ID: 19128465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER-2/neu overexpression is an independent prognostic factor for intestinal-type and early-stage gastric cancer patients.
    Liu W; Zhong S; Chen J; Yu Y
    J Clin Gastroenterol; 2012 Apr; 46(4):e31-7. PubMed ID: 22064554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER-2/neu gene amplification status in prostate cancer by fluorescence in situ hybridization.
    Ross JS; Sheehan C; Hayner-Buchan AM; Ambros RA; Kallakury BV; Kaufman R; Fisher HA; Muraca PJ
    Hum Pathol; 1997 Jul; 28(7):827-33. PubMed ID: 9224752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER-2/neu overexpression in patients with radically resected nonsmall cell lung carcinoma. Impact on long-term survival.
    Selvaggi G; Scagliotti GV; Torri V; Novello S; Leonardo E; Cappia S; Mossetti C; Ardissone F; Lausi P; Borasio P
    Cancer; 2002 May; 94(10):2669-74. PubMed ID: 12173335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients.
    Park S; Choi YL; Sung CO; An J; Seo J; Ahn MJ; Ahn JS; Park K; Shin YK; Erkin OC; Song K; Kim J; Shim YM; Han J
    Histol Histopathol; 2012 Feb; 27(2):197-207. PubMed ID: 22207554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material.
    Xu R; Perle MA; Inghirami G; Chan W; Delgado Y; Feiner H
    Mod Pathol; 2002 Feb; 15(2):116-24. PubMed ID: 11850540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER-2/Neu alterations in non-small cell lung cancer: a comprehensive evaluation by real time reverse transcription-PCR, fluorescence in situ hybridization, and immunohistochemistry.
    Pellegrini C; Falleni M; Marchetti A; Cassani B; Miozzo M; Buttitta F; Roncalli M; Coggi G; Bosari S
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3645-52. PubMed ID: 14506153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER-2/neu overexpression and amplification in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry, real-time reverse transcription-polymerase chain reaction, and fluorescence in situ hybridization.
    Odicino FE; Bignotti E; Rossi E; Pasinetti B; Tassi RA; Donzelli C; Falchetti M; Fontana P; Grigolato PG; Pecorelli S
    Int J Gynecol Cancer; 2008; 18(1):14-21. PubMed ID: 17451461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.